Medicaid GLP-1 coverage in Massachusetts, 2026.

MassHealth (Massachusetts Medicaid) does not cover Wegovy for weight loss.

Massachusetts last reviewed its drug list in 2026-07-03.

Most state Medicaid programs still exclude weight-loss-indication GLP-1, but the diabetes path is covered nearly everywhere with prior authorization (your doctor asks the plan to approve it first).

Coverage summary

IndicationCoverage
Wegovy (weight loss)No
Zepbound (weight loss)No
Ozempic / Mounjaro (type 2 diabetes)Yes
Compounded semaglutide / tirzepatideNo

Prior-authorization criteria

These rules come from the state preferred drug list (PDL), the list of drugs Massachusetts Medicaid has agreed to pay for.

CriterionValue
PA burdenMedium
BMI threshold (weight-loss path)Not applicable (weight-loss path not covered)
Comorbidity requiredNo
Last PDL update reviewed2026-07-03

What this means in practice

MassHealth ended coverage of weight-loss drugs on July 3, 2026 (Pharmacy Facts 271): Wegovy, Zepbound and Saxenda are no longer covered for obesity or overweight. GLP-1s remain covered for heart protection (BMI over 27 with established cardiovascular disease), MASH (a fatty liver disease) and sleep apnea (BMI over 30).

Managed-care organizations in Massachusetts

Massachusetts Medicaid pays private health plans, called managed-care organizations or MCOs, to run its coverage. An MCO has to cover at least what the state list covers and can add rules of its own. Check your own plan's current rules before you send anything in.

  • BMC HealthNet Plan
  • Fallon 365 Care
  • Mass General Brigham Health Plan
  • Tufts Health Together
  • WellSense Health Plan

Cash-pay alternatives if Medicaid does not cover you

MassHealth is the path. If denied, the appeal letter library applies.

If you end up paying cash, the GLP-1 cost guide has what each cash route costs, from the compounded floor to the manufacturer-direct brand prices. For ranked cash-pay options, see programs ranked by price and programs under $150 a month. Manufacturer savings cards and patient-assistance programs are not routes here: federal law bars the cards for anyone on Medicaid, and the free-drug programs require being uninsured.

If a supply gap rather than cost is blocking your refill, the GLP-1 shortage tracker shows which formulations the FDA lists as in shortage now. And if you are 65 or older and also have Medicare, the senior GLP-1 hub lays out the Medicare coverage paths for dual-eligible patients.

For the full cash-pay picture specific to Massachusetts, see the cheapest GLP-1 in Massachusetts guide.

19 GLP-1 clinical trials are recruiting in Massachusetts, and a study supplies its own study medication. Every site is listed on GLP-1 clinical trials in Massachusetts.

Take it to your prescriber: PA letter library

Massachusetts has no weight-loss path to appeal into. If you have type 2 diabetes, prior authorization is the route, and the letter library has the template your prescriber signs.

We keep a PA letter library with templates for 13 health plans, Anthem BCBS, Kaiser, Humana, Tricare and FEHB among them, sorted by the 7 clinical pictures that qualify. Each one cites the plan's own policy document, the diagnosis codes it asks for and the clinical trial evidence behind them.

If you have type 2 diabetes plus kidney disease and heart disease, that combination is the strongest case for approval in any state, and the templates cite the three clinical trials behind it.

If your PA is denied, the appeal letter library has denial-specific templates. For the commercial and Medicare coverage paths, see the GLP-1 insurance guide.

Massachusetts Medicaid GLP-1 FAQ

Does MassHealth (Massachusetts Medicaid) cover Wegovy for weight loss?
No. Massachusetts Medicaid does not cover Wegovy for the weight-loss indication as of the 2026-07-03 preferred drug list review. If you have type 2 diabetes, the diabetes-indicated GLP-1s (Ozempic, Mounjaro) may still be covered with prior authorization.
Does MassHealth (Massachusetts Medicaid) cover Zepbound for weight loss?
No. Massachusetts Medicaid does not cover Zepbound for the weight-loss indication as of the 2026-07-03 preferred drug list review. If you have type 2 diabetes, Mounjaro (tirzepatide, the same molecule as Zepbound) may be covered with prior authorization under the diabetes pathway.
Does MassHealth (Massachusetts Medicaid) cover Ozempic or Mounjaro for diabetes?
Yes. Massachusetts Medicaid covers Ozempic and Mounjaro for type 2 diabetes with prior authorization, usually after a trial of metformin. The diabetes pathway does not carry the BMI threshold that applies to the weight-loss pathway.
What if MassHealth (Massachusetts Medicaid) does not cover my GLP-1?
If your GLP-1 is not covered, the routes left do not run through Medicaid. A clinical trial costs nothing and many pay you for your time. Nobody checks your income. Manufacturer savings cards are not a route here, because federal law bars them for anyone on Medicaid. The cheapest route left is cash-pay compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy or Ozempic. The prices checked August 31, 2026 are on the chart. MassHealth is the path. If denied, the appeal letter library applies. If you were denied, the appeal letter library has denial-specific templates.

Other state Medicaid pages

See the full 51-state coverage table for the side-by-side view across every US state.

How we built this page

Compiled from each state Medicaid's published preferred drug list, PA criteria and PDL committee minutes. State Medicaid programs are not federally required to cover obesity drugs; the diabetes indication is covered nearly everywhere with PA. State-level data is point-in-time and shifts each PDL cycle. Always verify with your state Medicaid plan before relying on this page.

Last updated: 2026-08-28. We check each state Medicaid PDL and PA criteria quarterly. If you have recently had a different experience with Massachusetts Medicaid, email hello@glpchart.com with the details and we will check it.

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.